Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

The VIVA Trial | Synapse

March 18, 2003

The VIVA Trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

rhVEGF seems to be safe and well tolerated. rhVEGF offered no improvement beyond placebo in all measurements by day 60. By day 120, high-dose rhVEGF resulted in significant improvement in angina and favorable trends in ETT time and angina frequency.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Henry et al. (Tue,) studied this question.

synapsesocial.com/papers/69df46f6d5404a0bea592bf0 https://doi.org/https://doi.org/10.1161/01.cir.0000061911.47710.8a

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis.2000 · 69 citations
2Molecular effects of HMG-CoA reductase inhibitors on smooth muscle cell proliferation: Reply2001 · 4 citations
3Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.1994 · 602 citations
4Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial1998 · 46 citations
5Vascular endothelial growth factor administration in chronic myocardial ischemia1996 · 241 citations